2019 Q2 results - Thursday, July 18, 2019
|Key figures2||Continuing operations1|
|Net sales||11,764||11,339||4 (cc: 8)|
|Operating income||2,663||2,431||10 (cc: 17)|
|Net income||2,109||7,728||-73 (cc: -71)|
|EPS (USD)||0.91||3.32||-73 (cc: -71)|
|Free cash flow||3,612||3,268||11|
|Operating income||3,648||3,207||14 (cc: 20)|
|Net income||3,096||2,735||13 (cc: 19)|
|EPS (USD)||1.34||1.18||14 (cc: 20)|
- Refers to continuing operations as defined on page 42 of the Condensed Interim Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz (including the US generic oral solids and dermatology portfolio), as well as the continuing corporate functions.
- Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 55 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.
XBRL package Q2 2019
Documents Novartis results in XML format in line with requirements of the US Securities and Exchange Commission (SEC).
Novartis SEC Filings
In accordance with US securities regulations, Novartis files reports with the Securities and Exchange Commission. View all of the Novartis filings through EDGAR, the Electronic Data Gathering, Analysis and Retrieval system, on the SEC website.